The necessity of new clinical approaches regarding musculoskeletal system regeneration is evident. Nowadays different strategies such as autografts, allografts also used in synergy with cell therapy are already used in clinical treatments for moderate defects, but they face significant limitations due to limited supply, and risk of immune rejection. Currently, the treatments of extended osteochondral and bone defects involve invasive permanent metallic prosthesis, challenging reconstructive procedures and long rehabilitation period. Despite that, the gold standard seems to be far to obtain.

This content is only available via PDF.
You do not currently have access to this content.